IP Library Granted Patent US 10,005,741
Granted Patent B2
US 10,005,741 · App. 15/873,704 · Granted Jun 26, 2018

Therapeutic compounds

Inventors: Carl Wagner (Glendale, AZ); Pamela Marshall (Peoria, AZ); Peter Jurutka (Scottsdale, AZ)
Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
C07D249/18A61K31/505C07C57/50C07C223/06C07C309/31C07D209/08C07D213/48C07D213/74C07D213/79C07D215/227C07D235/10C07D239/42C07D241/20C07D241/28C07D307/79C07D333/54C07C2602/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,005,741
App. No.
15/873,704
Granted
Jun 26, 2018
Kind
B2
Abstract

The invention provides compounds and compositions that are useful for treating conditions including Alzheimer's disease, Parkinson's disease, diabetes, cancer, and psychotic disorders such as schizophrenia.

Claims (37)

1. A method for treating disease in an animal comprising administering a compound of formulae II to the animal, wherein the compound of formulae II is:

where:

X is N, Y is CH and Z is N;

X is N, Y is CH and Z is CH;

X is N, Y is N and Z is CH;

X is CH, Y is CH and Z is CH;

R 2 is H or methyl; and

R 3 is ethyl that is optionally substituted with one or more groups independently selected from F, Cl, and Br; wherein the ring containing X, Y, and Z is optionally substituted on carbon with one or more groups independently selected from halo;

or a pharmaceutically acceptable salt thereof;

provided the compound is not:

wherein the disease is Alzheimer's disease, Parkinson's disease, diabetes, cancer, or a psychotic disorder.

2. The method of claim 1 wherein the compound of formulae II is selected from formula IIa, IIb, and IIc:

wherein:

R 2 is H or methyl; and

R 3 is ethyl that is optionally substituted with one or more groups independently selected from F, Cl, and Br;

or a pharmaceutically acceptable salt thereof.

3. The method of claim 1 wherein the compound of formulae II is selected from formulae IIc:

wherein:

R 2 is H or methyl; and

R 3 is ethyl that is optionally substituted with one or more groups independently selected from F, Cl, and Br;

or a pharmaceutically acceptable salt thereof.

4. The method of claim 1 wherein the compound of formulae II is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

5. The method of claim 1 wherein the compound of formulae II is selected from formulae IIa and IIc:

wherein:

R 2 is H or methyl; and

R 3 is ethyl that is optionally substituted with one or more groups independently selected from F, Cl, and Br;

or a pharmaceutically acceptable salt thereof.

6. The method of claim 1 wherein the compound of formulae II is

or a pharmaceutically acceptable salt thereof.

7. The method of claim 1 wherein the compound of formulae II is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

8. The method of claim 1 wherein the compound of formulae II is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

9. A method for treating disease in an animal comprising administering a compound to the animal, wherein the compound is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof;

wherein the disease is Alzheimer's disease, Parkinson's disease, diabetes, cancer, or a psychotic disorder.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jul 9, 2021
From: ARIZONA STATE UNIVERSITY, TEMPE CAMPUS
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 056819/0462 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 20, 2018
From: WAGNER, CARL; MARSHALL, PAMELA; JURUTKA, PETER
To: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
Reel/Frame 045601/0140 →
Continuity (3)
Division 15121324
Provisional Application 61945020 · Feb 26, 2014
Related Publication 20180141921A1 · May 24, 2018